Is ARGX above its 150-day moving average?

ARGX is currently above its 150-day moving average by 2.82%. The MA150 sits at $815.49.

What is ARGX's RSI right now?

ARGX's 14-period RSI is 63.2. This is in a neutral zone (30–70).

Is ARGX's MACD bullish or bearish?

ARGX's MACD histogram reads +2.0375. A positive histogram means short-term momentum is leaning bullish.

How are ARGX's technical signals calculated?

Scanance computes ARGX's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

AR

argenx SE

ARGXHealthcareNASDAQ

Biotechnology · Last scanned May 29, 2026

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot

MA150+2.82%

$815.49

Price above medium-term moving average.

MA200+5.21%

$796.96

Above long-term trend line.

RSI-14neutral

63.2

Balanced. Not overbought, not oversold.

MACDpositive

+2.0375

Histogram positive — upward momentum.

Financials · Annual

Revenue

$4.15B

+89.6% YoY

Net Income

$1.29B

+55.1% YoY

EBITDA

$1.31B

+1146.3% YoY

Scan Results

Daily timeframe

1 of 4 indicators bullish as of May 28

DateIndicatorDetails

About argenx SE

argenx SE argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. Valued at $52.40B, ARGX is a large-cap name in its sector. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

Key stats

Market Cap$52.40B

P/E (TTM)36.49

Fwd P/E22.72

EPS$22.98

Beta-0.06

52W Change+46.3%

Analysis

argenx SE holds $4.44B in cash against $47.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Revenue has grown from $410.7M (2022) to $4.15B (2025), reflecting a 911% increase over the period.

The relatively low beta of -0.06 suggests ARGX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence argenx SE's trajectory.

Links

Company website ↗

argenx SE

News & analytics is part of Premium.

Technical readouts are part of Premium.